Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.
Jennifer S GravesMarius ThomasJun LiAnuja R ShahAlexandra GoodyearMarkus R LangeHeinz SchmidliDieter A HäringTim FriedeJutta GärtnerPublished in: Therapeutic advances in neurological disorders (2022)
This meta-analysis provides evidence that relapse rates are considerably higher with IFNs versus fingolimod or natalizumab. The results support the use of innovative Bayesian or non-inferiority designs to avoid exposing patients to less effective comparators in trials and bringing new medications to patients more efficiently.